ISU Specialty Chemical: Sharp Share Price Rally Against Thin Profits and High Multiples

Thesis

The data supports a story of fast revenue growth since the 2023 listing, with revenue rising from ₩117.5B in 2023 to ₩411.5B in 2025. The share price has risen 31.5% in one month, 38.2% in three months and 75.6% in one year, and sits below its 52-week high of ₩131,800 but well above its low of ₩44,400.

What the data does not support is a matching rise in profitability. Operating margin fell from 4.3% in 2024 to 0.4% in 2025 and is 2.7% on a trailing basis. Free cash flow is negative at about ₩112.3B. Investor flow, foreign ownership and short balance data are not available, and no news headlines were provided, so the reasons for the price move cannot be determined from this data.

Business overview

ISU Specialty Chemical is a KOSPI-listed chemicals company with a market cap of about ₩2.5T and 30,208,280 listed shares. Per the data it was founded on 2023-05-02 and listed on 2023-05-31. The CEO is 류승호. The data gives no description of products or customers, so the business is only visible through its numbers: revenue of ₩117.5B in 2023, ₩332.1B in 2024 (up 182.5%) and ₩411.5B in 2025 (up 23.9%). Trailing revenue through H1 2026 is ₩429.5B.

Financial analysis

Figures come from filed financial statements (DART). Operating income was a loss of ₩6.1B in 2023, a profit of ₩14.2B in 2024 and ₩1.6B in 2025. Net income followed the same path: a loss of ₩6.2B, a profit of ₩10.5B, then ₩0.8B.

On a trailing basis to H1 2026, operating income is ₩11.4B (2.7% margin) and net income is ₩6.6B (1.5% margin). ROE is 5.1%, versus 9.7% in 2024 and 0.6% in 2025.

The balance sheet shows liabilities to equity of 201.1%, cash of ₩34.5B and borrowings of ₩18.0B. Free cash flow is negative ₩112.3B, which suggests heavy investment or working capital use; the data does not break this down.

Valuation

On trailing figures the stock trades at a P/E of 385.2, a P/B of 18.4 and a P/S of 5.9. Enterprise value is about ₩2.53T. EV/EBITDA and dividend yield are not available. At the end of 2025, P/E was 2,323.9 and P/B was 13.5, so book-value multiples have risen since then while the earnings multiple has fallen as profits recovered from a very low base.

Peers are far lower on book value: LG Chem 0.5, Hanwha 0.6, Hanwha Solutions 0.6, KCC 0.4 and SKC 1.8. Hanwha shows a P/E of 10.3 and KCC 1.1, while the others have no P/E in the data. Peers are much larger by market cap, from ₩3.7T to ₩18.4T, and the comparison is only a rough guide.

Catalysts

• The half-year report for June 2026 was filed on 2026-08-14 and showed the trailing profit recovery to ₩11.4B in operating income.
• Investor relations events were filed on 2026-07-28, 2026-08-10, 2026-09-14 and 2026-09-28, indicating active outreach to investors.
• Repeated 5%+ holding reports (2026-06-08, 07-01, 07-14, 07-24 and 09-23) point to changes in major shareholder positions, though the data does not say who or in which direction.
• A corrected filing on new facility investment (2026-06-16) may relate to capital spending and the negative free cash flow.

Risks

• The P/E of 385.2 and P/B of 18.4 leave little room if profits do not grow substantially.
• Operating margin is thin at 2.7% and was only 0.4% in 2025, so small cost changes could erase profits.
• Free cash flow of negative ₩112.3B may need more financing, and a short-term borrowing increase decision was filed on 2026-07-07.
• Liabilities to equity of 201.1% shows meaningful leverage relative to the equity base.
• The share price rose 31.5% in one month, and investor flow, foreign ownership and short interest data are unavailable, so the drivers and the stability of the shareholder base are unclear.

Closing view

The data shows a young company that has grown revenue quickly and returned to profit, with the share price rallying strongly. However, margins are low, free cash flow is deeply negative and valuation multiples are far above both the company's thinner profit base and the peers shown. Missing flow, ownership and news data limit what can be said about why the shares have risen. The evidence is mixed: strong growth and recovering earnings on one side, stretched multiples and cash consumption on the other.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Report history

1. Oct 13, 2026InitiationISU Specialty Chemical: Sharp Share Price Rally Against Thin Profits and High Multiples